ROBERT J. FASS, M.D.
This content is PDF only. Please click on the PDF icon to access.
Nalidixic acid is a quinolonecarboxylic acid that was introduced into medical practice in 1963. As an orally given drug, it had a spectrum of activity as broad as that of kanamycin; most enterobacteria were susceptible, but Pseudomonas aeruginosa and enterococci were resistant. Its use was limited to the treatment of urinary tract infections because of low achievable blood concentrations. Although gastrointestinal, dermatologic, and neurologic (visual disturbances, confusion, hallucinations, seizures) effects were occasionally seen, therapy with the drug was relatively well tolerated (1).
Because of problems with bacterial resistance, nalidixic acid was never a very popular therapeutic agent. In one study
FASS RJ. The Quinolones. Ann Intern Med. 1985;102:400–402. doi: https://doi.org/10.7326/0003-4819-102-3-400
Download citation file:
Published: Ann Intern Med. 1985;102(3):400-402.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use